PMF
Also known as: Primary Myelofibrosis (PMF) / Primary Myelofibrosis / Primary Myelofibrosis (MF) / Myelofibrosis (PMF) / Myelofibrosis, Primary / Osteomyelofibrosis / Primary myelofibrosis (disorder) / Myelofibrosis (disorder) / Primary myelofibrosis (morphologic abnormality)
Drug | Drug Name | Drug Description |
---|---|---|
DB12500 | Fedratinib | Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.[L8090,L47016] |
DB08877 | Ruxolitinib | A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. |